JP2016530338A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530338A5
JP2016530338A5 JP2016543959A JP2016543959A JP2016530338A5 JP 2016530338 A5 JP2016530338 A5 JP 2016530338A5 JP 2016543959 A JP2016543959 A JP 2016543959A JP 2016543959 A JP2016543959 A JP 2016543959A JP 2016530338 A5 JP2016530338 A5 JP 2016530338A5
Authority
JP
Japan
Prior art keywords
alkylene
heterocyclyl
cycloalkyl
alkyl
membered heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016543959A
Other languages
English (en)
Japanese (ja)
Other versions
JP6494633B2 (ja
JP2016530338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/055966 external-priority patent/WO2015042077A1/en
Publication of JP2016530338A publication Critical patent/JP2016530338A/ja
Publication of JP2016530338A5 publication Critical patent/JP2016530338A5/ja
Application granted granted Critical
Publication of JP6494633B2 publication Critical patent/JP6494633B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016543959A 2013-09-22 2014-09-17 置換されているアミノピリミジン化合物および使用方法 Active JP6494633B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361880974P 2013-09-22 2013-09-22
US61/880,974 2013-09-22
US201461983444P 2014-04-23 2014-04-23
US61/983,444 2014-04-23
PCT/US2014/055966 WO2015042077A1 (en) 2013-09-22 2014-09-17 Substituted aminopyrimidine compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2016530338A JP2016530338A (ja) 2016-09-29
JP2016530338A5 true JP2016530338A5 (enExample) 2017-07-27
JP6494633B2 JP6494633B2 (ja) 2019-04-03

Family

ID=52689330

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016543960A Active JP6494634B2 (ja) 2013-09-22 2014-09-17 置換されているアミノピリミジン化合物および使用方法
JP2016543959A Active JP6494633B2 (ja) 2013-09-22 2014-09-17 置換されているアミノピリミジン化合物および使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016543960A Active JP6494634B2 (ja) 2013-09-22 2014-09-17 置換されているアミノピリミジン化合物および使用方法

Country Status (12)

Country Link
US (4) US9670194B2 (enExample)
EP (2) EP3046563B1 (enExample)
JP (2) JP6494634B2 (enExample)
KR (2) KR20160060100A (enExample)
AU (2) AU2014321420B2 (enExample)
BR (1) BR112016003229A8 (enExample)
CA (2) CA2918938C (enExample)
MX (2) MX2016003456A (enExample)
MY (2) MY176421A (enExample)
RU (2) RU2675105C9 (enExample)
SG (2) SG11201600707QA (enExample)
WO (3) WO2015042078A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016003229A8 (pt) * 2013-09-22 2020-02-04 Calitor Sciences Llc composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
NZ726608A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CA2952025A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
NZ726360A (en) * 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
EA201692266A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
CU24428B1 (es) 2014-07-04 2019-06-04 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
CN105924433B (zh) * 2015-02-28 2020-12-22 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2016149160A1 (en) * 2015-03-15 2016-09-22 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
US9981965B2 (en) * 2015-03-31 2018-05-29 Synthon B.V. Process for preparing idelalisib
CN106146502B (zh) * 2015-04-09 2019-01-04 上海医药工业研究院 艾代拉里斯的合成方法及制备中间体
CN106146352A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 Idelalisib中间体及其制备方法
CN106146411A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 (s)-2-(1-氨基-丙基)-5-氟-3-苯基-3h-喹唑啉-4-酮的制备方法
CN106279171A (zh) * 2015-06-09 2017-01-04 南京安源生物医药科技有限公司 一种Idelalisib的制备方法
EP3347097B1 (en) * 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
JP6913100B2 (ja) * 2015-11-04 2021-08-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Btk阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法
NZ741294A (en) * 2015-11-17 2023-07-28 Merck Patent Gmbh Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
AU2016378723B2 (en) 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN105669733A (zh) * 2016-01-29 2016-06-15 上海毕路得医药科技有限公司 一种1-甲基-1h-吡唑-3-硼酸频哪醇酯的合成方法
WO2017130221A1 (en) * 2016-01-29 2017-08-03 Sun Pharmaceutical Industries Limited Improved process for the preparation of idelalisib
EP3411376A1 (en) * 2016-02-03 2018-12-12 Lupin Limited A process for the preparation of phosphatidylinositol 3-kinase inhibitor
WO2017191608A1 (en) * 2016-05-05 2017-11-09 Laurus Labs Limited Novel process for preparation of idelalisib
KR101932146B1 (ko) * 2016-07-14 2018-12-24 주식회사 바이오웨이 Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물
CN107648237B (zh) * 2016-07-26 2022-03-04 江苏豪森药业集团有限公司 氨基嘧啶类化合物的药物组合物及其制备方法
CN108017641B (zh) * 2016-11-02 2021-01-05 深圳铂立健医药有限公司 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
CN107056810B (zh) * 2017-02-09 2019-04-26 广东省中医院 一种喹诺酮羧酸衍生物的制备方法
AU2018288841B2 (en) 2017-06-21 2022-09-29 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease
CN110003192A (zh) * 2018-01-04 2019-07-12 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
US20230201202A1 (en) * 2020-05-27 2023-06-29 Duke University Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
CN115785084B (zh) * 2022-08-26 2024-01-16 广东东阳光药业股份有限公司 嘧啶衍生物及其在药物中的应用
WO2025021943A1 (en) * 2023-07-26 2025-01-30 Neuralis Quinazolinone, benzoxazinone and benzoxazepinone derivatives as protein kinase inhibitors

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0633776B1 (en) 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
SI0957087T1 (en) 1994-06-15 2003-04-30 The Wellcome Foundation Limited Intermediates useful in the preparation of enzyme inhibitors
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
EA000890B1 (ru) 1995-04-14 2000-06-26 Глаксо Веллкам Инк. Дозирующий ингалятор для албутерола
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997002266A1 (en) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN1923818A (zh) 1996-04-12 2007-03-07 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
HK1043788A1 (zh) 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
BR0114323A (pt) 2000-09-29 2003-07-01 Glaxo Group Ltd Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto
DK1337527T3 (da) 2000-11-07 2010-01-04 Novartis Ag Indolylmaleinimidderivater som proteinkinase C-inhibitorer
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003059899A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1490062E (pt) 2002-03-26 2008-01-30 Boehringer Ingelheim Pharma Miméticos de glucocorticóides, métodos para a sua preparação, composições farmacêuticas e suas utilizações
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0312575A (pt) 2002-07-08 2005-05-03 Pfizer Prod Inc Moduladores do receptor de glicocorticóides
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
JP2006504678A (ja) 2002-08-21 2006-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
US20050245588A1 (en) 2002-09-20 2005-11-03 Amjad Ali Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1578411A4 (en) 2002-12-09 2007-05-02 Univ Texas PROCESS FOR THE SELECTIVE INHIBITION OF JANUS TYROSINE KINASE3 (JAK3)
PT1699512E (pt) 2003-11-03 2012-09-11 Glaxo Group Ltd Dispositivo distribuidor de fluido
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
EP1749827A4 (en) 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd ANTITUMOR AGENTS
CN102229609A (zh) 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
ATE517882T1 (de) 2004-10-19 2011-08-15 Hoffmann La Roche Chinolinderivate
JP2010513567A (ja) * 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリミジン
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CN101952292A (zh) 2007-11-13 2011-01-19 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
KR101660050B1 (ko) 2008-01-04 2016-09-26 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
KR20150144817A (ko) * 2011-06-10 2015-12-28 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US20130143902A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
CN104768952B (zh) 2012-08-08 2016-10-19 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
PE20150637A1 (es) 2012-10-16 2015-05-08 Almirall Sa Derivados de pirrolotriazinona como inhibidores de pi3k
CA2895782C (en) 2012-12-21 2017-08-22 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
BR112015014592A2 (pt) 2012-12-21 2017-07-11 Gilead Calistoga Llc composto, composição farmacêutica, e, método para o tratamento de um humano
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
US9216985B2 (en) 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
EP3008053B1 (en) 2013-06-14 2018-03-21 Gilead Calistoga LLC Phosphatidylinositol 3-kinase inhibitors
BR112016003229A8 (pt) * 2013-09-22 2020-02-04 Calitor Sciences Llc composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica

Similar Documents

Publication Publication Date Title
JP2016530338A5 (enExample)
JP2016534146A5 (enExample)
ES2549862T3 (es) Derivados de triazol como inhibidores de quinasa
KR102012268B1 (ko) 염증성 질환의 치료를 위한 신규의 다이하이드로피리미디노아이소퀴놀리논 및 그의 약학 조성물
ES2708211T3 (es) 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
JP7558334B2 (ja) PI3K-γ阻害剤としてのアミノピラジンジオール化合物
US10590077B2 (en) TRPV4 antagonists
ES2505290T3 (es) Derivados de 3,4,4A,10B-tetrahidro-1H-tiopirano[4,3-c]isoquinolina
ES2807221T3 (es) Derivados de 4-azaindol
BRPI0720043A2 (pt) Composto oxadiazol
JP7244504B2 (ja) PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
KR20180132806A (ko) 단백질 조정제로서 유용한 헤테로시클릭 아미드
JP2012140432A5 (enExample)
JP2016507581A5 (enExample)
EP3515887A1 (en) Trpv4 antagonists
EP3515888A1 (en) Trpv4 antagonists
JP2013522316A5 (enExample)
WO2020010003A1 (en) AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
TW202229273A (zh) 稠合雜芳基化合物及其作為CaMKII抑制劑之用途
JP2010537994A5 (enExample)
JP2013543512A5 (enExample)
CN105924434A (zh) 取代的氨基嘧啶类化合物及其使用方法和用途
JP2016539993A5 (enExample)
BR122025015788A2 (pt) Compostos de aminopirazina diol, seus usos como inibidores de pi3k- gama e composição farmacêutica dos mesmos
EA045434B1 (ru) СОЕДИНЕНИЯ АМИНОПИРАЗИНДИОЛА КАК ИНГИБИТОРЫ PI3Kγ